The objective of this study was to evaluate the differences and predictive efficacy of circulating cell-free DNA (cfDNA) and human suppression of tumorigenesis 2 (ST2) among women with uncomplicated pregnancies and patients with gestational hypertension (GH) or preeclampsia (PE). This study included patients with GH (n = 41), patients with PE (n = 62), and women with uncomplicated pregnancies (n = 148). The cfDNA concentration was determined by qPCR, and the ST2 levels were measured by ELISA. A receiver operating characteristic curve was employed to measure the diagnostic performance of cfDNA and ST2. Our results showed that ST2 but not cfDNA was increased in the middle and third trimesters of normal pregnancy; ST2 and cfDNA were increased in GH and PE patients compared to women with uncomplicated pregnancies. More importantly, plasma cfDNA and ST2 served as diagnostic biomarkers for GH and PE, and the AUCs were 0.883 and 0.734 for GH and 0.838 and 0.816 for PE, respectively. Moreover, their combination significantly elevated the diagnostic efficiency for GH and PE, with AUCs of 0.906 and 0.916, respectively. Plasma cfDNA and ST2 could be used as parameters for GH and PE.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Audibert F, et al. The hypertensive disorders of pregnancy (29.3). Best Pract Res Clin Obstet Gynaecol. 2015;29:643–57.
Eche S, Mackraj I, Moodley J. Circulating fetal and total cell-free DNA, and sHLA-G in black South African women with gestational hypertension and pre-eclampsia. Hypertens Pregnancy. 2017;36:295–301.
Walentowicz-Sadlecka M, Domaracki P, Sadlecki P, Siodmiak J, Grabiec M, Walentowicz P, et al. Assessment of the SFlt-1 and sFlt-1/25(OH)D ratio as a diagnostic tool in gestational hypertension (GH), preeclampsia (PE), and gestational diabetes mellitus (GDM). Dis Markers. 2019;2019:1–10.
Antwi E, Amoakoh-Coleman M, Vieira DL, Madhavaram S, Koram K, Grobbee DE, et al. Systematic review of prediction models for gestational hypertension and preeclampsia. PLoS ONE. 2020;15:e230955.
Lewandowska M, Sajdak S, Marciniak W, Lubiński J. First trimester serum copper or zinc levels, and risk of pregnancy-induced hypertension. Nutrients. 2019;11:2479.
Guo J, Liu G, Guo G. Association of insulin resistance and autonomic tone in patients with pregnancy-induced hypertension. Clin Exp Hypertens. 2018;40:476–80.
Guibourdenche J, Leguy M, Tsatsaris V. Biology and markers of preeclampsia. Ann Biol Clin-Paris. 2013;71:79–87.
Gogoi P, Sinha P, Gupta B, Firmal P, Rajaram S. Neutrophil-to-lymphocyte ratio and platelet indices in pre-eclampsia. Int J Gynecol Obstet. 2019;144:16–20.
Sibai BM. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol. 2006;30:16–9.
Osoti AO, Page ST, Richardson BA, Guthrie BL, Kinuthia J, Polyak SJ, et al. Postpartum metabolic syndrome after gestational hypertension and preeclampsia, a prospective cohort study. Pregnancy Hypertens. 2019;18:35–41.
Sun F, Qian W, Zhang C, Fan JX, Huang HF. Correlation of maternal serum homocysteine in the first trimester with the development of gestational hypertension and preeclampsia. Med Sci Monit. 2017;23:5396–401.
Trottmann F, Baumann M, Amylidi-Mohr S, Surbek D, Risch L, Mosimann B, et al. Angiogenic profiling in HELLP syndrome cases with or without hypertension and proteinuria. Eur J Obstet Gynecol Reprod Biol. 2019;243:93–6.
Giannakou K, Evangelou E, Papatheodorou SI. Genetic and non-genetic risk factors for pre-eclampsia: umbrella review of systematic reviews and meta-analyses of observational studies. Ultrasound Obst Gyn. 2018;51:720–30.
Rolnik DL, O’Gorman N, Fiolna M, van den Boom D, Nicolaides KH, Poon LC. Maternal plasma cell-free DNA in the prediction of pre-eclampsia. Ultrasound Obst Gyn. 2014;45:106–11.
Ekambaram P, Jayachandran T, Dhakshinamoorthy L. Differential expression of HSP90α and heme oxygenase in cord blood RBC during preeclampsia. Toxicol Mech Method. 2012;23:113–9.
Tamara S, Tinnakorn C, Roberto R. Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. J Matern Fetal Neonatal Med. 2013;26:1359–70.
Rahul K, Richard TL. The IL‑33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Disco. 2008;7:827–40.
Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-γ production. Eur J Immunol. 2009;39:1046–55.
Granne I, Southcombe JH, Snider JV, Tannetta DS, Child T, Redman CW. et al. ST2 and IL-33 in pregnancy and pre-eclampsia. PLoS One. 2011;6:e24463.
Kong W, Gong Y, Zhou R, Wang Y, Zhang Y, Luo X, et al. Soluble ST2, a preeclampsia-related cytokine receptor, is transported bi-directionally across the placenta. Placenta. 2018;63:21–5.
Kaitu U-Lino TUJ, Tuohey L, Tong S. Maternal serum interleukin-33 and soluble ST2 across early pregnancy, and their association with miscarriage. J Reprod Immunol. 2012;95:46–9.
Salvianti F, Inversetti A, Smid M, Valsecchi L, Candiani M, Pazzagli M, et al. Prospective evaluation of RASSF1A cell-free DNA as a biomarker of pre-eclampsia. Placenta 2015;36:996–1001.
Zhou N, Liu L, Li D, Zeng Q, Song X. VCS parameters of neutrophils, monocytes and lymphocytes may indicate local bacterial infection in cancer patients who accepted cytotoxic chemotherapeutics. Eur J Clin Microbiol. 2016;35:41–8.
Huang L, Sauve R, Birkett N, Dean F, van Walraven C. Maternal age and risk of stillbirth: a systematic review. CMAJ. 2008;178:165–72.
Hahn S, Rusterholz C, Hösli I, Lapaire O. Cell-free nucleic acids as potential markers for preeclampsia. Placenta 2011;32:S17–20.
Foidart JM, Schaaps JP, Chantraine F, Munaut C, Lorquet S. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia—a step forward but not the definitive answer. J Reprod Immunol. 2009;82:106–11.
This study was supported by grants from the National Key R&D Program of China (2017YFC1001403 and 2019YFA0802600) and NSFC (31871512 and 31671199) to CZ. Support was also obtained from the Ji’nan Clinical Medical Science Technology Innovation Program (201704080) and the Shanghai Commission of Science and Technology (17DZ2271100).
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liu, L., Li, H., Wang, N. et al. Assessment of plasma cell-free DNA and ST2 as parameters in gestational hypertension and preeclampsia. Hypertens Res (2021). https://doi.org/10.1038/s41440-021-00650-0
- Circulating cell-free DNA (cfDNA)
- Human suppression of tumorigenesis 2 (ST2)
- Gestational hypertension